A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial)

被引：1
|
作者：
Mirza, M. R. [1 ,2 ]
Monk, B. J. [3 ]
Oza, A. [4 ]
Mahner, S. [5 ,6 ]
Redondo, A. [7 ,8 ]
Fabbro, M. [9 ,10 ]
Ledermann, J. [11 ,12 ]
Lorusso, D. [13 ,14 ]
Vergote, I. B. [15 ,16 ]
Rosengarten, O. [17 ,18 ]
Berek, J. [19 ]
Herrstedt, J. [20 ,21 ]
Tinker, A. V. [22 ]
Dubois, A. [23 ,24 ]
Gonzalez Martin, A. [25 ,26 ]
Follana, P. [27 ,28 ]
Benigno, B. [29 ]
Rimel, B. J. [30 ]
Agarwal, S. [31 ]
Matulonis, U. [32 ]
机构：
[1] NSGO, Dept Oncol 5073, Copenhagen, Denmark
[2] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark
[3] Univ Arizona, Canc Ctr Phoenix, Dept Oncol, Phoenix, AZ USA
[4] Univ Hlth Network, Dept Oncol, Toronto, ON, Canada
[5] AGO, Dept Gynegol, Hamburg, Germany
[6] Univ Munich, Hamburg, Germany
[7] GEICO, Dept Oncol, Madrid, Spain
[8] Univ Hosp, Madrid, Spain
[9] GINECO, Dept Oncol, Montpellier, France
[10] Inst Canc Montpellier, Montpellier, France
[11] NCRI, Dept Med Oncol, London, England
[12] UCL, London, England
[13] MITO MaNGO, Dept Gynecol Oncol, Milan, Italy
[14] Fdn IRCCS Natl Canc Inst, Milan, Italy
[15] BGOG, Dept Obstet & Gynecol, Leuven, Belgium
[16] Univ Leuven, Leuven, Belgium
[17] ISGO, Dept Gynecol Oncol, Jerusalem, Israel
[18] Shaare Zedek Med Ctr, Jerusalem, Israel
[19] Stanford Womens Canc Ctr, Dept Oncol, Stanford, CA USA
[20] NSGO, Dept Oncol, Odense, Denmark
[21] Odense Univ Hosp, Odense, Denmark
[22] British Columbia Canc Agcy, Dept Med, Vancouver, BC, Canada
[23] AGO, Dept Oncol, Essen, Germany
[24] Kliniken Essen Mitte, Essen, Germany
[25] GEICO, Med Oncol Dept, Madrid, Spain
[26] MD Anderson Canc Ctr Madrid, Madrid, Spain
[27] GINECO, Dept Med Oncol, Nice, France
[28] Ctr Antoine Lacassagne, Nice, France
[29] Univ Gynecol Oncol, Dept Gynecol Oncol, Atlanta, GA USA
[30] Cedars Sinai Med Ctr, Dept Obstet & Gynecol, West Hollywood, CA USA
[31] Tesaro Inc, Dept Med Affairs, Waltham, MA USA
[32] Dana Farber Canc Inst, Dept Gynecol Oncol, Boston, MA 02115 USA
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw435.26
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA3_PR
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A Randomized, Double-Blind Phase 3 Trial of Maintenance Therapy With Niraparib vs Placebo in Patients With Platinum-Sensitive Recurrent Ovarian Cancer (ENGOT-OV16/NOVA Trial)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (12) : 3 - 5
  • [2] A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial).
    Matulonis, Ursula
    Mahner, Sven
    Wenham, Robert Michael
    Ledermann, Jonathan A.
    Monk, Bradley J.
    Campo, Jose Maria Dei
    Berek, Jonathan S.
    Vergote, Ignace
    Fabbro, Michel
    Katsaros, Dionyssios
    Marth, Christian
    Lorusso, Domenica
    Herrstadt, Jorn
    Agarwal, Shefali
    Martell, Robert E.
    Mirza, Mansoor Raza
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] ENGOT-OV16/NOVA: A PHASE 3 RANDOMIZED DOUBLE-BLIND TRIAL OF MAINTENANCE WITH PARP-INHIBITOR NIRAPARIB VERSUS PLACEBO IN PATIENTS WITH PLATINUM-SENSITIVE OVARIAN CANCER.
    Mirza, M.
    Berek, J. S.
    Vergote, I.
    Wenham, R. M.
    Del Campo, J. M.
    Oza, A. M.
    Mahner, S.
    Monk, B. J.
    Fabbro, M.
    Ledermann, J. A.
    Marth, C.
    Bruchim, I.
    Katsaros, D.
    Lorusso, D.
    Malander, S.
    Dorum, A.
    Agarwal, S.
    Martell, R. E.
    Matulonis, U.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 33 - 34
  • [4] ENGOT-OV16/NOVA: A MAINTENANCE STUDY WITH NIRAPARIB VERSUS PLACEBO IN PATIENTS WITH PLATINUM-SENSITIVE OVARIAN CANCER
    Matulonis, U.
    Herrstedt, J.
    Oza, A.
    Mahner, S.
    Redondo, A.
    Fabbro, M.
    Ledermann, J.
    Lorusso, D.
    Vergote, I.
    Rosengarten, O.
    Reinthaller, A.
    Madry, R.
    Monk, B. J.
    Dorum, A.
    Tinker, A. V.
    DuBois, A.
    Gonzalez Martin, A.
    Follana, P.
    Berek, J. S.
    Gilbert, L.
    Benigno, B.
    Rosenberg, P.
    Rimel, B. J.
    Buscema, J.
    Balser, J.
    Agarwal, S.
    Mirza, M. R.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 19 - 20
  • [5] Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial
    Oza, Amit M.
    Matulonis, Ursula A.
    Malander, Susanne
    Hudgens, Stacie
    Sehouli, Jalid
    del Campo, Josep M.
    Berton-Rigaud, Dominique
    Banerjee, Susana
    Scambia, Giovanni
    Berek, Jonathan S.
    Lund, Bente
    Tinker, Anna V.
    Hilpert, Felix
    Palacio Vazquez, Isabel
    D'Hondt, Veronique
    Benigno, Benedict
    Provencher, Diane
    Buscema, Joseph
    Agarwal, Shefali
    Mirza, Mansoor R.
    LANCET ONCOLOGY, 2018, 19 (08): : 1117 - 1125
  • [6] Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial
    del Campo, Josep M.
    Matulonis, Ursula A.
    Malander, Susanne
    Provencher, Diane
    Mahner, Sven
    Follana, Philippe
    Waters, Justin
    Berek, Jonathan S.
    Woie, Kathrine
    Oza, Amit M.
    Canzler, Ulrich
    Gil-Martin, Marta
    Lesoin, Anne
    Monk, Bradley J.
    Lund, Bente
    Gilbert, Lucy
    Wenham, Robert M.
    Benigno, Benedict
    Arora, Sujata
    Hazard, Sebastien J.
    Mirza, Mansoor R.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (32) : 2968 - +
  • [7] FINAL OVERALL SURVIVAL AND LONG-TERM SAFETY IN THE ENGOT-OV16/NOVA PHASE 3 TRIAL OF NIRAPARIB IN PATIENTS WITH RECURRENT OVARIAN CANCER
    Marme, Frederik
    Matulonis, Ursula
    Herrstedt, Jorn
    Oza, Amit
    Mahner, Sven
    Redondo, Andres
    Berton, Dominique
    Berek, Jonathan S.
    Haslund, Charlotte A.
    Gonzalez-Martin, Antonio
    Becourt, Stephanie
    Tinker, Anna V.
    Ledermann, Jonathan
    Benigno, Benedict
    Lindahl, Gabriel
    Colombo, Nicoletta
    Malinowska, Izabela A.
    Liu, Wenlei
    Schmitz, Michael H. A.
    Monk, Bradley J.
    Mirza, Mansoor R.
    ANTICANCER RESEARCH, 2023, 43 (07) : 3363 - 3364
  • [8] LONG-TERM SAFETY OF NIRAPARIB IN PATIENTS WITH RECURRENT OVARIAN CANCER: RESULTS FROM THE ENGOT-OV16/NOVA TRIAL
    Juden, Lisa Marie
    Freese, Esther
    Bessette, Paul
    Bover Barcelo, Isabel M.
    Matulonis, Ursala A.
    Mirza, Mansoor R.
    ONCOLOGY NURSING FORUM, 2019, 46 (02)
  • [9] Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: Results from the ENGOT-OV16/NOVA Trial
    Oza, A. M.
    Matulonis, U. A.
    Malander, S.
    Sehouli, J.
    del Campo, J. M.
    Berthon-Rigaud, D.
    Banerjee, S.
    Scambia, G.
    Berek, J. S.
    Lund, B.
    Tinker, A. V.
    Hilpert, F.
    Palacio Vazquez, I.
    D'Hondt, V.
    Benigno, B.
    Provencher, D. M.
    Buscema, J.
    Hudgens, S.
    Agarwal, S.
    Mirza, M. R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [10] FINAL OVERALL SURVIVAL AND LONG-TERM SAFETY IN THE ENGOT-OV16/NOVA PHASE 3 TRIAL OF NIRAPARIB IN PATIENTS WITH RECURRENT OVARIAN CANCER
    Mirza, Mansoor R.
    Herrstedt, Jorn
    Oza, Amit
    Mahner, Sven
    Redondo, Andres
    Berton, Dominique
    Berek, Jonathan S.
    Haslund, Charlotte A.
    Marme, Frederik
    Gonzalez-Martin, Antonio
    Becourt, Stephanie
    Tinker, Anna V.
    Ledermann, Jonathan
    Benigno, Benedict
    Lindahl, Gabriel
    Colombo, Nicoletta
    Malinowska, Izabela A.
    Liu, Wenlei
    Monk, Bradley J.
    Matulonis, Ursula
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A15 - A16
12345